Prognostic Assessment in Patients with Indolent B-Cell Lymphomas
Follicular lymphoma (FL) is an indolent lymphoma with long median survival. Many studies have been performed to build up prognostic scores potentially useful to identify patients with poorer outcome. In 2004, an international consortium coordinated by the International Follicular Lymphoma Prognostic...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/107892 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548992213319680 |
|---|---|
| author | Luca Arcaini Sara Rattotti Manuel Gotti Stefano Luminari |
| author_facet | Luca Arcaini Sara Rattotti Manuel Gotti Stefano Luminari |
| author_sort | Luca Arcaini |
| collection | DOAJ |
| description | Follicular lymphoma (FL) is an indolent lymphoma with long median survival. Many studies have been performed to build up prognostic scores potentially useful to identify patients with poorer outcome. In 2004, an international consortium coordinated by the International Follicular Lymphoma Prognostic Factor project was established and a new prognostic study was launched (FLIPI2) using progression-free survival (PFS) as main endpoint and integrating all the modern parameters prospectively collected. Low-grade non-Hodgkin lymphomas were once considered as a heterogenous group of lymphomas characterized by an indolent clinical course. Each entity is characterized by unique clinicobiologic features. Some studies have been focused on prognostic factors in single lymphoma subtypes, with the development of specific-entity scores based on retrospective series, for instance splenic marginal zone lymphoma (SMZL). A widely accepted prognostic tool for clinical usage for indolent non-follicular B-cell lymphomas is largely awaited. In this paper we summarized the current evidence regarding prognostic assessment of indolent follicular and non-follicular lymphomas. |
| format | Article |
| id | doaj-art-1a4d03844ad64669b5ddc7b18130334a |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-1a4d03844ad64669b5ddc7b18130334a2025-02-03T06:12:29ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/107892107892Prognostic Assessment in Patients with Indolent B-Cell LymphomasLuca Arcaini0Sara Rattotti1Manuel Gotti2Stefano Luminari3Division of Hematology, Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, ItalyDivision of Hematology, Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, ItalyDivision of Hematology, Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, ItalyDivision of Oncology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, 41124 Modena, ItalyFollicular lymphoma (FL) is an indolent lymphoma with long median survival. Many studies have been performed to build up prognostic scores potentially useful to identify patients with poorer outcome. In 2004, an international consortium coordinated by the International Follicular Lymphoma Prognostic Factor project was established and a new prognostic study was launched (FLIPI2) using progression-free survival (PFS) as main endpoint and integrating all the modern parameters prospectively collected. Low-grade non-Hodgkin lymphomas were once considered as a heterogenous group of lymphomas characterized by an indolent clinical course. Each entity is characterized by unique clinicobiologic features. Some studies have been focused on prognostic factors in single lymphoma subtypes, with the development of specific-entity scores based on retrospective series, for instance splenic marginal zone lymphoma (SMZL). A widely accepted prognostic tool for clinical usage for indolent non-follicular B-cell lymphomas is largely awaited. In this paper we summarized the current evidence regarding prognostic assessment of indolent follicular and non-follicular lymphomas.http://dx.doi.org/10.1100/2012/107892 |
| spellingShingle | Luca Arcaini Sara Rattotti Manuel Gotti Stefano Luminari Prognostic Assessment in Patients with Indolent B-Cell Lymphomas The Scientific World Journal |
| title | Prognostic Assessment in Patients with Indolent B-Cell Lymphomas |
| title_full | Prognostic Assessment in Patients with Indolent B-Cell Lymphomas |
| title_fullStr | Prognostic Assessment in Patients with Indolent B-Cell Lymphomas |
| title_full_unstemmed | Prognostic Assessment in Patients with Indolent B-Cell Lymphomas |
| title_short | Prognostic Assessment in Patients with Indolent B-Cell Lymphomas |
| title_sort | prognostic assessment in patients with indolent b cell lymphomas |
| url | http://dx.doi.org/10.1100/2012/107892 |
| work_keys_str_mv | AT lucaarcaini prognosticassessmentinpatientswithindolentbcelllymphomas AT sararattotti prognosticassessmentinpatientswithindolentbcelllymphomas AT manuelgotti prognosticassessmentinpatientswithindolentbcelllymphomas AT stefanoluminari prognosticassessmentinpatientswithindolentbcelllymphomas |